共 50 条
- [21] APACHE: An open label, randomized, phase 2 study of the anti-programmed death-ligand 1 (PD-L1) durvalumab (D, MEDI4736), alone or in combination with tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)ANNALS OF ONCOLOGY, 2016, 27Necchi, A.Mariani, L.Anichini, A.Giannatempo, P.Raggi, D.Togliardi, E.Calareso, G.Di Genova, N.Crippa, F.Salvioni, R.
- [22] Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodiesLUNG CANCER MANAGEMENT, 2014, 3 (02) : 175 - 190Yang, Lu-LuWu, Yi-Long
- [23] Efficacy and safety of programmed cell death-1/programmed cell death ligand-1 inhibitors in advanced urothelial malignancy: A systematic review and meta-analysisINDIAN JOURNAL OF UROLOGY, 2019, 35 (02) : 101 - 115Pattanaik, SmitaDey, SumitJaiswal, NishantRohilla, RachnaSingh, Shrawan KumarMandal, Arup KumarMavuduru, Ravimohan Suryanarayan
- [24] Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naive patients (pts) with EGFR mutant NSCLCJOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S79 - S79Gibbons, D. L.Chow, L. Q.Kim, D-W.Kim, S-W.Yeh, T.Song, X.Jiang, H.Taylor, R.Karakunnel, J.Creelan, B.
- [25] Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung CancerMOLECULES AND CELLS, 2021, 44 (05) : 363 - 373Lee, Yong JunLee, Jii BumHa, Sang-JunKim, Hye Ryun
- [26] Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experienceEXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (09) : 1047 - 1059Vitale, GiovanniLamberti, GiuseppeComito, FrancescaDi Nunno, VincenzoMassari, FrancescoMorelli, Maria CristinaArdizzoni, AndreaGelsomino, Francesco
- [27] Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor TherapiesARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2024, 148 (07) : 757 - 774Sholl, Lynette M.Awad, MarkRoy, Upal BasuBeasley, Mary BethCartun, Richard WalterHwang, David M.Kalemkerian, GregoryLopez-Rios, FernandoMino-Kenudson, MariPaintal, AjitReid, KearinRitterhouse, LaurenSouter, Lesley A.Swanson, Paul E.Ventura, Christina B.Furtado, Larissa V.
- [28] CHECKPOINT INHIBITION WITH SYSTEMIC ANTI-PROGRAMMED CELL DEATH LIGAND-1 AND INTRAVESICAL TMX-101 DECREASE TUMOR BURDEN IN A MOUSE MODEL OF UROTHELIAL CARCINOMAJOURNAL OF UROLOGY, 2017, 197 (04): : E1313 - E1313Lenis, AndrewChamie, KarimYao, ShiyinCarson, DennisHayashi, Tomoko
- [29] Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic ReviewsFRONTIERS IN IMMUNOLOGY, 2022, 13Ou, Shun-LongLuo, JingWei, HuaQin, Xiao-LiDu, Su-YaWang, SongJiang, Qian
- [30] A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Ott, Patrick AlexanderCallahan, Margaret K.Odunsi, KunlePark, Andrew J.Pan, Linda S.Venhaus, Ralph RudolphKarakunnel, Joyson JosephHodi, F. StephenWolchok, Jedd D.